At Qlaris, our lead program is QLS-111, a novel topical ocular therapy that lowers intraocular pressure with a unique mechanism of action. QLS-111 is distinct from currently available therapies by selectively targeting episcleral venous pressure (EVP) and improving outflow distal to the trabecular meshwork. This novel mechanism may enable the improved treatment of diseases where EVP has limited therapy or has itself been pathologic, such as Normal Tension Glaucoma, Primary Open Angle Glaucoma, glaucoma associated with Sturge-Weber Syndrome, and also in combination with Minimally-Invasive Glaucoma Surgery (MIGS) devices.
Company Details
- Employees
- 9
- Founded
- 2019
- Address
- 55 William St, Wellesley,massachusetts 02481,united States
- Industry
- Biotechnology
- Website
- qlaris.bio
- HQ
- Wellesley, Massachusetts
Qlaris Bio, Inc. Questions
Qlaris Bio, Inc.'s website is qlaris.bio
Qlaris Bio, Inc.'s LinkedIn profile is https://www.linkedin.com/company/qlaris-bio-inc
Qlaris Bio, Inc. has
9 employees.
View email and phone details for 9
employees at Qlaris Bio, Inc..
Qlaris Bio, Inc.'s industry is
Biotechnology
Qlaris Bio, Inc.'s top competitors are
Context Therapeutics,
Latus Bio,
Myeyes,
Ocugen,
Abeona Therapeutics,
Delphia Therapeutics,
Ocular Therapeutix, Inc.,
Enlaza Therapeutics,
Aurion Biotech,
Humonix Biosciences, Inc..
Qlaris Bio, Inc.'s categories are Biotechnology
Qlaris Bio, Inc.'s founding year is 2019
